The Effectiveness of Trimetazidine Treatment in Patients with Stable Angina Pectoris of Various Durations: Results from the CHOICE-2 Study
|
01.07.2018 |
Glezer M.
Uskov V.
Goncharenko I.
Prasolova T.
Guseva V.
Shinkar A.
Samsonova S.
Vikhrova I.
Kuz’kina S.
Mitina L.
Timofeeva I.
Archakova T.
Kovaleva N.
Romanova E.
Tivon Y.
Antonova Y.
Kurganova O.
Davydova N.
Klyuchantseva O.
Popovskaya Y.
Kharitonova E.
Kuzmina T.
Buzmakova K.
Kaplenko L.
Pospelova N.
Stepanova A.
Kolbasheva N.
Krasnova G.
Pal’vinskaya A.
Toloknova V.
Bikmullina R.
Gainullina A.
Kedrina E.
Mikhailova S.
Nabiullina T.
Nizamova A.
Uskova A.
Yushkova A.
Andreeva O.
Fedotova G.
Bessergeneva O.
Gavrilyuk D.
Ehalo N.
Zlobina M.
Zhemartseva E.
Markushina I.
Pavlovets V.
Sobolenko A.
Apanovich I.
Kireeva N.
Maksimova I.
Butz T.
Pavlova I.
Bachurina S.
Orlyachenko S.
Zaitseva T.
Beznogova V.
Litsis N.
Novozhenina A.
Abramyan L.
Adamyan M.
Askerko S.
Bolmosov A.
Vasilieva I.
Volodova S.
Grishko P.
Zherebetskaya E.
Zemlyanaya N.
Klyshnikova L.
Kononchik E.
Kuznetsova N.
Kuz’minova I.
Marmurova I.
Mikhailova R.
Mordovina I.
Nazarkina O.
Perepechko A.
Pivovarova N.
Potapova T.
Prokofiev D.
Proniushkina N.
Savelieva E.
Semovskikh N.
Timonenkova L.
Fomin V.
Furman O.
Tsutsieva R.
Chibrikina M.
Shoshina I.
Yashchenko E.
Bocharova T.
Demyanenko O.
Zhukova L.
Melnikov A.
Merkulieva I.
Tyasina E.
Pakholkova N.
Rogozina S.
Chugunova I.
Brazhnik M.
|
Advances in Therapy |
|
0 |
Ссылка
© 2018, The Author(s). Introduction: Trimetazidine (TMZ) has been shown to reduce angina symptoms and to increase exercise capacity in randomized clinical trials, but more extensive data would be useful to assess its effects in real-world clinical practice and in patients with different durations of disease. Methods: CHOICE-2 was a Russian, multicenter, 6-month, open-label, prospective observational study that assessed the effect of adding TMZ modified release 35 mg bid to antianginal treatment in a real-world setting. The present analysis of CHOICE-2 results explored the effects of adding TMZ to background antianginal therapies with regard to the duration of stable angina. Results: A total of 741 patients with known durations of disease were divided into four groups according to stable angina pectoris (AP) duration, ranging from less than 1 year to more than 9 years. Addition of TMZ led to a significant decrease in the frequency of angina attacks and in the use of short-acting nitrates in all groups. In patients with recently diagnosed angina (AP duration < 1 year), the average number of angina attacks per week decreased significantly from 3.75 ± 4.63 to 0.67 ± 1.51 and in those with advanced disease (AP duration > 9 years) from 5.63 ± 5.24 to 1.32 ± 2.07. Angina-free walking distance also improved significantly. Addition of TMZ also improved patient well-being. Results were achieved rapidly (within 2 weeks), were maintained over 6 months, and were obtained in all patient groups regardless of angina duration. Conclusion: TMZ added to other antianginal therapies proved to be effective for reducing angina attacks and short-acting nitrate use, increasing angina-free walking distance, and improving patient well-being in a real-life setting, irrespective of angina duration, including patients with recently diagnosed angina. This provides an opportunity for intensification of treatment early on in the disease process, with the aim of decreasing angina burden and improving patient quality of life. Funding: Servier. Trial Registration: ISRCTN identifier ISRCTN65209863. Plain Language Summary: Plain language summary available for this article.
Читать
тезис
|
The place of strontium ranelate in the treatment of patients with osteoporosis (results of the MARC program)
|
01.01.2018 |
Nikitinskaya O.
Toroptsova N.
Nasonov E.
|
Nauchno-Prakticheskaya Revmatologiya |
|
0 |
Ссылка
© 2018 Ima-Press Publishing House. All right reserved. Strontium ranelate (SR) that has a proven efficacy in reducing the risk of fractures and in increasing bone mineral density is currently recommended as a second choice drug for the treatment of severe osteoporosis (OP) in postmenopausal women and elderly men. Subjects and methods. In 2014-2015, a survey within the framework of the MARC program (The Use of Antiosteoporotic Drugs in Real Clinical Practice) was conducted in 1799 OP patients aged 25 to 92 years, who had been treated for this disease for at least one year. Among the respondents, there were 1696 people aged 50 years and older (mean age, 64±7 years; disease duration, 2.7±2.4 years) (86% women and 14% men) who were the subjects of this survey. Adherence to performed antiosteoporotic therapy was evaluated within the last 12 months before the survey by the following parameters: which drug had been taken; the number of packages used, treatment gaps and compliance with the treatment regimen. Results and discussion. The survey of the patients included in the study showed that 19% of them had received SR at any time over the course of the disease, and 8% had taken the drug within the year preceding the survey. Thus, SR remains a popular drug in real clinical practice for the treatment of severe OP in patients with no history of coronary heart disease, uncontrolled hypertension, cerebrovascular diseases, peripheral artery disease, and a predisposition to thrombosis and thromboembolism.
Читать
тезис
|